Artificial IntelligenceHigh Priority (8/10)Usa

Lilly Doubles Down on Insilico's AI Medicines, Bets Up to $2.75B

Eli Lilly is expanding its partnership with Insilico Medicine, investing $115 million upfront with potential milestones up to $2.75 billion to use AI-powered drug discovery platforms for oral drugs against various diseases.

Key Points

  • Lilly commits $115 million upfront with potential milestones up to $2.75 billion
  • Partnership uses Insilico's AI platforms for oral drug development
  • Builds on Lilly's existing AI partnership with NVIDIA for drug discovery
  • Represents one of the largest pharmaceutical AI deals to date

Full Details

Eli Lilly is significantly expanding its partnership with Insilico Medicine, committing $115 million upfront with potential milestone payments reaching up to $2.75 billion. The deal leverages Insilico's machine learning platforms for oral drug development against a variety of diseases. The two companies will collaborate on multiple R&D programs centered on targets of Lilly's choosing, utilizing Insilico's AI platforms. This agreement builds on Lilly's broader AI push, including a partnership last year with NVIDIA to build a supercomputer for drug discovery optimization. Andrew Adams, Lilly's group vice president of Molecule Discovery, called Insilico's AI-enabled engine 'a powerful complement to Lilly's deep expertise in clinical development.' The partnership represents one of the largest pharmaceutical AI deals to date.

Why It Matters

The massive investment signals AI drug discovery is moving from experimental to mainstream, potentially accelerating the entire pharmaceutical development timeline and reducing costs.

Sourcebiospace.com

Get stories like this delivered daily

AI-curated news, personalized to your interests. Zero noise.

Start 7-Day Free Trial →

More in Artificial Intelligence